

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1,2	'a qualitative study' (full title line 2, abstract line 36-37)
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3	lines 36-58
<b>Introduction</b>				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-6	lines 71-132
Objectives	3	State specific objectives, including any prespecified hypotheses	6	lines 132-136
<b>Methods</b>				
Study design	4	Present key elements of study design early in the paper	10	lines 225
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	9-11	Setting and location: lines 206-222 Date reporting: - Recruitment line 236-245, - Data collection period lines 248, as appropriate for qualitative study reporting (SRQR Checklist item 10) - The concept of 'exposure' is not appropriate for this study design
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	10	Lines 257-263 explain eligibility criteria ' <i>Participants were eligible to participate if they were 18 years or older, had a diagnosis of hypertension, and had been in care for at least six months</i> '. Lines 250-258 describe the purposive sampling strategy (SRQR Checklist item 8), as appropriate for the qualitative study design.
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed		Not applicable to this study design

		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case		
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable		Not applicable to this study design
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group		Not applicable to this study design
Bias	9	Describe any efforts to address potential sources of bias	12 34-35	Purposive sampling strategy: line 257-266 Strengths and limitations of study: lines 742-784
Study size	10	Explain how the study size was arrived at	11	Line 237

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	14	Lines 301-302 ‘FGD and IDI participants provided verbal and written informed consent as well as their demographic data for descriptive analysis’
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding		Not applicable to this study design
		(b) Describe any methods used to examine subgroups and interactions		Not applicable to this study design
		(c) Explain how missing data were addressed		Not applicable to this study design
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy		
		(e) Describe any sensitivity analyses		Not applicable to this study design
		<b>Results</b>		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	15	Line 305-314 (results section)
		(b) Give reasons for non-participation at each stage	15	Line 309-310
		(c) Consider use of a flow diagram		Not applicable to this study design
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	15	Line 305-312 (results section)
		(b) Indicate number of participants with missing data for each variable of interest		Not applicable to this study design
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)		Not applicable to this study design
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time		Not applicable to this study design
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure		Not applicable to this study design
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures		Not applicable to this study design
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included		Not applicable to this study design
		(b) Report category boundaries when continuous variables were categorized		Not applicable to this study design

(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not applicable to this study design
--	-------------------------------------

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses		Not applicable to this study design
<b>Discussion</b>				
Key results	18	Summarise key results with reference to study objectives	30	Lines 641-651
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	35	Lines 773-784
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	35	Lines 773-784
Generalisability	21	Discuss the generalisability (external validity) of the study results	34,35	Lines 742-784 as appropriate to study design
<b>Other information</b>				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	36	Included in funding statement, Line 810-815

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.